Mathew Anoop, Moolla Muhammad, Jeemon Panniyammakal, Punnoose Eapen, Ashraf S M, Pisharody Sunil, Viswanathan Sunitha, Jayakumar T G, Jabir Abdullakutty, Mathew Jubil P, John Thomas, Thomas Vinod, Bainey Kevin
Division of Cardiology, Mazankowski Alberta Heart Institute, University of Alberta,112 St NW, Edmonton, AB T6G 2B7, Canada.
Division of Cardiology, MOSC Medical College Hospital, Kolenchery, Kerala, 682311, India.
Postgrad Med J. 2025 Feb 19;101(1193):232-239. doi: 10.1093/postmj/qgae129.
Transatlantic guidelines endorse quality metrics for timely reperfusion in patients with ST-elevation myocardial infarction (STEMI). Compliance in low- and middle-income countries (LMICs) is largely unknown.
We prospectively evaluated 2928 STEMI patients in Kerala, India, across 16 PCI-capable hospitals who received reperfusion with either primary percutaneous coronary intervention (PPCI) or fibrinolysis. Primary endpoint was a major adverse cardiovascular event (MACE) composite of death, non-fatal myocardial infarction, stroke or readmission for heart failure at 1-year.
Among reperfused STEMI patients, 320 (10.9%) received timely reperfusion with either PPCI or fibrinolysis, 1985 (67.8%) received delayed PPCI, and 623 (21.3%) received delayed fibrinolysis. Timely reperfusion had lower unadjusted MACE rates than delayed PCI or fibrinolysis (timely reperfusion: 11.9%, delayed PPCI: 13.6%, delayed fibrinolysis: 23.9%, P < 0.001). Mortality was lowest in the timely reperfusion group (timely reperfusion: 6.3%, delayed PPCI: 7.8%, delayed fibrinolysis 18.8%, P < 0.001). After multivariate analysis, delayed fibrinolysis had a higher MACE rate (HR 1.52 95% CI 1.04-2.21) and mortality (HR 1.97, 95% CI 1.18-3.25) compared to timely reperfusion. Total ischemic time > 3 h and delayed first medical contact-to-needle time predicted MACE at 1 year.
Among STEMI patients in Kerala, India, only one in 10 eligible patients received timely reperfusion. Longer total ischemic times and delayed fibrinolysis were associated with 1-year MACE. Improving timely reperfusion is critical to enhancing STEMI outcomes in LMICs. What is already known on this topic Given the established link between delay to reperfusion and worse major adverse cardiac events (MACE), global efforts have concentrated on minimizing different components of the total ischemic time to improve ST-elevation myocardial infarction (STEMI) outcomes. Compliance in low- and middle-income countries (LMICs) is largely unknown. What this study adds In this cohort of STEMI patients in Kerala, India, total ischemic time and first medical contact-to-needle time correlated with long-term MACE rates, whereas other timeliness indicators did not. How this study might affect research, practice or policy Our study highlights the significant barriers to accessing STEMI care that are prevalent in LMICs despite incremental growth in the number of PCI-capable hospitals. The pre-hospital phase within total ischemic time is the most important quality improvement metric of STEMI care in LMICs, especially for patients chosen for fibrinolysis.
跨大西洋指南认可了ST段抬高型心肌梗死(STEMI)患者及时再灌注的质量指标。低收入和中等收入国家(LMICs)的依从情况大多未知。
我们对印度喀拉拉邦16家具备PCI能力的医院的2928例STEMI患者进行了前瞻性评估,这些患者接受了直接经皮冠状动脉介入治疗(PPCI)或溶栓治疗进行再灌注。主要终点是1年时死亡、非致命性心肌梗死、中风或因心力衰竭再次入院组成的主要不良心血管事件(MACE)复合终点。
在接受再灌注的STEMI患者中,320例(10.9%)通过PPCI或溶栓治疗获得了及时再灌注,1985例(67.8%)接受了延迟PPCI,623例(21.3%)接受了延迟溶栓治疗。与延迟PCI或溶栓治疗相比,及时再灌注的未调整MACE发生率更低(及时再灌注:11.9%,延迟PPCI:13.6%,延迟溶栓治疗:23.9%,P<0.001)。及时再灌注组的死亡率最低(及时再灌注:6.3%,延迟PPCI:7.8%,延迟溶栓治疗:18.8%,P<0.001)。多因素分析后,与及时再灌注相比,延迟溶栓治疗的MACE发生率更高(HR 1.52,95%CI 1.04 - 2.21),死亡率更高(HR 1.97,95%CI 1.18 - 3.25)。总缺血时间>3小时和首次医疗接触至穿刺时间延迟可预测1年时的MACE。
在印度喀拉拉邦的STEMI患者中,每10例符合条件的患者中只有1例获得了及时再灌注。总缺血时间延长和延迟溶栓治疗与1年时的MACE相关。改善及时再灌注对于提高LMICs中STEMI的治疗效果至关重要。关于该主题已知的信息鉴于再灌注延迟与更差的主要不良心脏事件(MACE)之间已确立的联系,全球努力集中在尽量减少总缺血时间的不同组成部分,以改善ST段抬高型心肌梗死(STEMI)的治疗效果。低收入和中等收入国家(LMICs)的依从情况大多未知。本研究的补充内容在印度喀拉拉邦的这一队列STEMI患者中,总缺血时间和首次医疗接触至穿刺时间与长期MACE发生率相关,而其他及时性指标则不然。本研究可能对研究、实践或政策产生的影响我们的研究突出了尽管具备PCI能力的医院数量有所增加,但LMICs中普遍存在的获得STEMI治疗的重大障碍。总缺血时间中的院前阶段是LMICs中STEMI治疗最重要的质量改进指标,尤其是对于选择溶栓治疗的患者。